好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Smartphone Cognitive Assessments in Adults with Early-onset Cognitive Changes: Feasibility, Acceptability, and Validity
Aging, Dementia, and Behavioral Neurology
P7 - Poster Session 7 (8:00 AM-9:00 AM)
12-007
To assess the feasibility, acceptability, and preliminary validity of a smartphone-based cognitive assessment in adults from racial and ethnic groups reflective of the US population who report subjective cognitive changes.
Digital health technologies can expand access to cognitive assessment, yet few studies have evaluated these for use in early-onset dementia research. BEYONDD is a multi-site observational study that validates biomarkers of early-onset cognitive and behavioral changes in underrepresented populations.
Participants from the BEYONDD cohort were invited to complete remotely delivered smartphone-based cognitive assessments (ALLFTD m-app), including executive function and episodic memory tasks. Participants also completed self-report questionnaires of technology familiarity, subjective cognitive concerns, and emotional reactions to the app.  Analyses of covariance (ANCOVAs), controlling for age, sex, and education, quantified group differences in BEYONDD participants who endorsed subjective cognitive concerns compared to a sample of 123 healthy control participants from the Brain Health Registry. To enhance demographic representativeness, the normative comparison group was selected to match the BEYONDD cohort in age, sex, education, and racial/ethnic composition.
The sample included 63 participants (52 ± 6.9 years; 76% female; 43% non-Latino Black, 36% Latino, 10% non-Latino Asian, 8% multiracial). 98% reported high smartphone confidence. Adherence was high, with all participants completing all tests, and 97% found the time requirement acceptable. Emotional responses were largely positive, with 55% indicating enjoyment or excitement versus anxiety (23%), sadness (11%), or frustration (7%). After adjusting for age, sex, and education, greater confusion severity was associated with poorer executive function (b = −0.38, p < 0.001) and memory performance (b = −0.47, p = 0.004). 
Smartphone-based cognitive assessments were feasible, acceptable, and sensitive to self-reported cognitive changes. These results suggest that remote phone-based assessments may provide an avenue for enhancing access to research for non-traditional participants. 
Authors/Disclosures
Amy Wise
PRESENTER 		Ms. Wise has nothing to disclose.
Melissa Sotelo Ms. Sotelo has nothing to disclose.
Eden Barragan, PhD Dr. Barragan has nothing to disclose.
Ashley Heywood, PhD Dr. Heywood has nothing to disclose.
Ray Fregly, MS The institution of an immediate family member of Mr. Fregly has received research support from NIH. The institution of an immediate family member of Mr. Fregly has received research support from CPRIT. An immediate family member of Mr. Fregly has received intellectual property interests from a discovery or technology relating to health care.
Emily Paolillo, PhD The institution of Dr. Paolillo has received research support from NIH/NIA.
Hilary W. Heuer (UCSF Memory and Aging Center) No disclosure on file
Sreya Dhanam, BS Ms. Dhanam has nothing to disclose.
Mark Sanderson-Cimino Dr. Sanderson-Cimino has nothing to disclose.
Jack Taylor, MS Mr. Taylor has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Meyes Squibb. The institution of Mr. Taylor has received research support from National Institute of Health.
Joshua D. Downer, PhD Dr. Downer has nothing to disclose.
Anjali Sadarangani, Research Coordinator Ms. Sadarangani has nothing to disclose.
Rachel L. Nosheny, PhD An immediate family member of Prof. Nosheny has received personal compensation for serving as an employee of Google. The institution of Prof. Nosheny has received research support from NIH. The institution of Prof. Nosheny has received research support from Genentech. The institution of Prof. Nosheny has received research support from California Department of Public Health. The institution of Prof. Nosheny has received research support from Lilly.
Michael W. Weiner, MD Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dolby Family Ventures. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuicals. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acumen Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoibnt. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Owkin France. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Quantum Leap Health. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sai MedPartners. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MEDA Corp.. Dr. Weiner has stock in Anven. Dr. Weiner has stock in Alzeca. Dr. Weiner has stock in Alzheon, Inc.. Dr. Weiner has stock in ALZpath. The institution of Dr. Weiner has received research support from NIH/NIA; National Institutes of Health/National Institutes of Aging. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Speaker/Presenter with Merck Sharp & Dohme. Dr. Weiner has received personal compensation in the range of $0-$499 for serving as a Speaker/Presenter with BrightFocus Foundation. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Speaker/Presenter with Banner Health.
scott mackin Prof. mackin has nothing to disclose.
Winnie Kwang Ms. Kwang has nothing to disclose.
Monica R. Camacho Mrs. Camacho has nothing to disclose.
Katherine L. Possin, PhD (U of CA San Francisco, Neurology) Dr. Possin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ClearView Healthcare Partners. The institution of Dr. Possin has received research support from Quest Diagnostics. The institution of Dr. Possin has received research support from NIH. The institution of Dr. Possin has received research support from The Global Brain Health Institute. The institution of Dr. Possin has received research support from The Rainwater Foundation.
Desiree Byrd, PhD Dr. Byrd has nothing to disclose.
Monica Rivera Mindt, PhD Dr. Rivera Mindt has nothing to disclose.
Gil D. Rabinovici, MD, FAAN (UCSF Memory & Aging Center) Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Norodisk. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for C2N. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Peerview. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Topic Chair, Course Director and teacher with AAN. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with ANA.
Adam L. Boxer, MD, PhD (University of California, San Francisco) An immediate family member of Dr. Boxer has received personal compensation for serving as an employee of Kaiser Permanente. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono. Dr. Boxer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Oscotec. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arrowhead. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine Biosciences. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Switch. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvinas. Dr. Boxer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alector. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Transposon. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Boxer has stock in Alector. Dr. Boxer has stock in Arvinas. Dr. Boxer has stock in Neurovanda. The institution of Dr. Boxer has received research support from Biogen. The institution of Dr. Boxer has received research support from Eisai. The institution of Dr. Boxer has received research support from Regeneron. The institution of Dr. Boxer has received research support from NIH. The institution of Dr. Boxer has received research support from Bluefield Project-5. Dr. Boxer has received research support from Rainwater Charitable Foundation. Dr. Boxer has received research support from GHR Foundation. Dr. Boxer has received intellectual property interests from a discovery or technology relating to health care.
Adam Staffaroni Adam Staffaroni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Adam Staffaroni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Aviado Bio. Adam Staffaroni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CervoMed. Adam Staffaroni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Prevail Therepeutics/Eli Lilly. Adam Staffaroni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. The institution of Adam Staffaroni has received research support from NIH. The institution of Adam Staffaroni has received research support from Bluefield Project To Cure FTD. The institution of Adam Staffaroni has received research support from AFTD/ALSA. Adam Staffaroni has received personal compensation in the range of $500-$4,999 for serving as a Scientific Advisory Board member with AADF.